The ARF1 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered for loss-of-function studies of the ARF1 gene. This knockout model is generated via CRISPR/Cas9-mediated gene disruption, creating a heterogeneous pool of A-549 cells with targeted ablation of ARF1 expression. The polyclonal format provides a versatile tool for investigating ARF1-dependent cellular processes without the need for single-cell cloning, preserving the genetic diversity of the host cell background while enabling robust functional assays.
The host cell line, A-549, is a human alveolar basal epithelial cell line originally derived from a 58-year-old Caucasian male with lung adenocarcinoma. A-549 cells serve as a well-established model for studying alveolar epithelial biology, respiratory diseases, and lung cancer. They exhibit characteristics of type II alveolar epithelial cells and are widely employed in cancer biology, drug metabolism, and toxicology research. Their relevance to lung adenocarcinoma makes them particularly suited for exploring oncogenic signaling and tumor-associated secretory phenotypes.
ARF1 encodes a small GTPase that regulates intracellular membrane trafficking and Golgi homeostasis. It cycles between inactive GDP-bound and active GTP-bound states, controlled by GEFs (GBF1, BIG1/2) and GAPs (ARFGAP1). Upon activation, ARF1 recruits coatomer to Golgi membranes, facilitating COPI vesicle formation for retrograde Golgi-to-ER transport. ARF1 also interacts with phospholipase D and PI4P kinase, and governs AP-1 adaptor assembly at the trans-Golgi network. Furthermore, ARF1 is regulated by EGFR-mediated PI3K/AKT signaling, which modulates its Golgi localization. Consequently, ARF1 is essential for secretion, endosomal recycling, and signal integration.
In the context of A-549 lung adenocarcinoma cells, ARF1 plays a pivotal role in orchestrating secretory trafficking that supports cancer cell proliferation, migration, and invasion. Dysregulation of ARF1-dependent pathways can enhance the secretion of matrix metalloproteinases and growth factors, contributing to a pro-metastatic niche. Moreover, ARF1-mediated Golgi organization is essential for sustaining the aberrant signaling networks driven by oncogenic EGFR and PI3K/AKT in lung adenocarcinoma. Disruption of ARF1 using this polyclonal knockout population enables researchers to dissect the contributions of ARF1 to Golgi integrity, protein secretion, and tumorigenic phenotypes, providing a physiologically relevant model to study the molecular mechanisms underlying lung cancer progression.
The ARF1 Knockout A-549 Polyclonal Cells support diverse applications. Immunofluorescence microscopy with Golgi markers (GM130, TGN46) and Western blotting confirm knockout effects. Transwell assays evaluate cell migration, while RT-qPCR profiles transcriptional changes. Cell viability assays enable chemotherapeutic screening and identification of synthetic lethal interactions. This model is ideal for studying secretory trafficking, COPI dynamics, and signaling in lung adenocarcinoma. For more information, please contact Ascent Research.
